Cost-Effectiveness of Varenicline Versus Bupropion, Nicotine-Replacement Therapy, and Unaided Cessation in Greece

Clinical Therapeutics

Volumn 34, Issue 8, 2012, Pages 1803-1814

  Athanasakis, Kostas ^a   Igoumenidis, Michael ^b   Karampli, Eleftheria ^a   Vitsou, Elli ^c   Sykara, Georgia ^c   Kyriopoulos, John ^a  

^a NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^b TECHNOLOGICAL EDUCATIONAL INSTITUTE OF LAMIA   (Greece)

^c PFIZER INC   (United States)

Author keywords

Cost effectiveness analysis; Greece; Nicotine replacement therapy; Smoking; Smoking cessation aids; Varenicline

Indexed keywords

AMFEBUTAMONE; NICOTINE; VARENICLINE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; GREECE; HEALTH CARE COST; HUMAN; ISCHEMIC HEART DISEASE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY; NICOTINE REPLACEMENT THERAPY; PREVALENCE; SMOKING CESSATION; SOCIAL SECURITY; STROKE; TOBACCO DEPENDENCE;

BENZAZEPINES; BUPROPION; COMPUTER SIMULATION; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG COSTS; GREECE; HEALTH CARE COSTS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MARKOV CHAINS; MODELS, ECONOMIC; MONTE CARLO METHOD; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; QUINOXALINES; SMOKING; SMOKING CESSATION; TIME FACTORS; TOBACCO USE CESSATION PRODUCTS; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 84864624724     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.07.002     Document Type: Article

References (48)

1. WHO Report on the Global Tobacco Epidemic, 2009: Implementing Smoke-free Environments World Health Organization (WHO), Accessed April 4, 2011. http://whqlibdoc.who.int/publications/2009/9789241563918_eng_full.pdf.
2. Bolin K., Lindgren B. Smoking, healthcare cost, and loss of productivity in Sweden 2001. Scand J Public Health 2007, 35:187-196.
3. Orme M.E., Hogue S.L., Kennedy L.M., et al. Development of the health and economic consequences of smoking interactive model. Tob Control 2001, 10:55-61.
4. The Health Benefits of Smoking Cessation: A Report of the Surgeon General 1990, US Dept. of Health and Human Services, US DHHS, Atlanta, Ga.
5. World Health Organization Policy Recommendations for Smoking Cessation and Treatment of Tobacco Dependence 2003 World Health Organization, Accessed April 12, 2011. http://www.who.int/tobacco/resources/publications/tobacco_dependence/en/.
6. Fiore M., Jae'n C.R., Baker T.B., et al. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A US Public Health Service report. Am J Prev Med 2008, 35:158-176.
7. Stead L.F., Perera R., Bullen C., et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008, 1. CD000146.
8. Vemer P., Rutten-van Mölken M.P. Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries. Value Health 2010, 13:230-241.
9. Raw M., Regan S., Rigotti N., et al. A survey of tobacco dependence treatment guidelines in 31 countries. Addiction 2009, 104:1243-1250.
10. Jorenby D.E., Hays J.T., Rigotti N.A., et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial [published correction appears in JAMA. 2006;296:1355]. JAMA 2006, 296:56-63.
11. The European Tobacco Control Report 2007 World Health Organization (WHO) Regional Office for Europe, Accessed March 29, 2012. http://www.euro.who.int/__data/assets/pdf_file/0005/68117/E89842.pdf.
12. Athanasakis K., Souliotis K., Kyriopoulos J. Economic consequences of smoking on health systems: an appraisal for Greece [in Greek]. Iatriki 2010, 98:109-115.
13. Martínez-Sánchez J., Fernández E., Fu M., et al. Smoking behaviour, involuntary smoking, attitudes towards smoke-free legislations, and tobacco control activities in the European Union. PLoS One 2010, 5:e13881.
14. Howard P., Knight C., Boler A., et al. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model: application to a population of US adult smokers. Pharmacoeconomics 2008, 26:497-511.
15. European Detailed Mortality Database (DMDB) (updated June 2011) World Health Organization (WHO), Accessed December 12, 2011. http://data.euro.who.int/dmdb/index.php.
16. Fernández de Bobadilla Osorio J., Sánchez-Maestre C., Brosa Riestra M., et al. Cost effectiveness analysis of varenicline (Champix) for the treatment of smoking in Spain [in Spanish]. An Med Interna 2008, 25:342-348.
17. Hoogendoorn M., Welsing P., Rutten-van Mölken M.P. Cost-effectiveness of varenicline compared with bupropion, NRT and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin 2008, 24:51-61.
18. Sichletidis L., Tsiotsios I., Gavriilidis A., et al. Prevalence of chronic obstructive pulmonary disease and rhinitis in northern Greece. Respiration 2005, 72:270-277.
19. Minas M., Koukosias N., Zintzaras E., et al. Prevalence of chronic diseases and morbidity in primary health care in central Greece: An epidemiological study. BMC Health Serv Res 2010, 10:252.
20. Vemmos K.N., Bots M.L., Tsibouris P.K., et al. Stroke incidence and case fatality in southern Greece: the Arcadia Stroke Registry. Stroke 1999, 30:363-370.
21. Truelsen T., Piechowski-Jóźwiak B., Bonita R., et al. Stroke incidence and prevalence in Europe: a review of available data. Eur J Neurol 2006, 13:581-598.
22. Italian cancer figures, report 2010: Cancer prevalence in Italy. Patients living with cancer, long-term survivors and cured patients [in Italian]. Epidemiol Prev 2010, 34(Suppl 2):1-188. AIRTUM Working Group.
23. Ferlay J., Shin H.R., Bray F., et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 Accessed May 10, 2011. http://globocan.iarc.fr.
24. de Marco R., Accordini S., Cerveri I., et al. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med 2007, 175:32-39.
25. Panhellenic Survey for the Evaluation of Health and Health Services 2011, National School of Public Health, National School of Public Health, Athens, Greece.
26. Thun M.J., Apicella L.F., Henley S.J. Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. JAMA 2000, 284:706-712.
27. Feenstra T.L., Hamberg-van Reenen H.H., Hoogenveen R.T., et al. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. Value Health 2005, 8:178-190.
28. Orme M.E., Hogue S.L., Kennedy L.M., et al. Development of the health and economic consequences of smoking interactive model. Tob Control 2001, 10:55-61.
29. Gonzales D., Rennard S.I., Nides M., et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006, 296:47-55.
30. Nides M., Glover E.D., Reus I.V., et al. Varenicline versus bupropion for smoking cessation: a pooled analysis. Am J Health Behav 2008, 32:664-675.
31. Silagy C., Lancaster T., Stead L., et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004, (3). CD000146.
32. Foulds J., Burke M., Steinberg M., et al. Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs 2004, 9:39-53.
33. Maniadakis N., Fragoulakis V., Pallis A.G., et al. Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis. Ann Oncol 2010, 21:1462-1467.
34. Maniadakis N., Tzanakis N., Fragoulakis V., et al. Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece. Curr Med Res Opin 2006, 22:1599-1607.
35. Drummond M.F., Sculpher M.J., Torrance G.W., et al. Methods for Economic Health Evaluation of Health Care Programmes 2005, Oxford University Press, Oxford. 3rd ed.
36. Fiscella K., Franks P. Cost effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counselling. JAMA 1996, 275:1247-1251.
37. Spencer M., Briggs A.H., Grossman R.F., et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005, 23:619-637.
38. Mannino D.M., Buist A.S., Petty T.L., et al. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003, 58:388-393.
39. Trippoli S., Vaiani M., Lucioni C., et al. Quality of life and utility in patients with non-small cell lung cancer. Pharmacoeconomics 2001, 19:855-863.
40. Duncan P.W., Lai S.M., Keighley J. Defining post-stroke recovery: implications for design and interpretation of drug trials. Neuropharmacology 2000, 39:835-841.
41. Tengs T.O., Lin T.H. A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics 2003, 21:191-200.
42. Gage B.F., Cardinalli A.B., Owens D.K. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke 1998, 29:1083-1091.
43. Hay J.W., Sterling K.L. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease. Pharmacoeconomics 2005, 23:133-141.
44. Maniadakis N., Ekman M., Fragoulakis V., et al. Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece. Eur J Health Econ 2011, 12:253-261.
45. Rasch A., Lenz C., Greiner W. Health economic model of smoking cessation treatment with varenicline in Germany. Value Health 2008, 10:A472-A473.
46. Bolin K., Wilson K., Benhaddi H., et al. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation-results from four European countries. Eur J Public Health 2009, 19:650-654.
47. Keating G., Lyseng-Williamson K.A. Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation. Pharmacoeconomics 2010, 28:231-254.
48. Lundborg P. Does smoking increase sick leave?. Evidence using register data on Swedish workers. Tob Control 2007, 16:114-118.